Floatz logo

Vocimagene Amiretrorepvec

Sarcoma

Tocagen Inc.gene_therapyPhase 1Dormant
C
34/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
21/ 100
Competitive Position
73/ 100

Competitive context

110 Active assets in the Sarcoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
Essen Biotech
Phase 2BB
Ifosfamide
City of Hope Medical Center
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Roswell Park Cancer Institute
Phase 2BB
Carboplatin
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Vocimagene Amiretrorepvec is also rated in:

anaplastic astrocytomaDormant
CCC
Indicative ·
48 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
48 / 100
View asset →
anaplastic oligodendrogliomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →